Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study
- 1 February 2012
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 106 (2), 257-268
- https://doi.org/10.1016/j.rmed.2011.07.020
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca LP
This publication has 26 references indexed in Scilit:
- The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A ReviewCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2010
- Exacerbations and lung function decline in COPD: New insights in current and ex-smokersRespiratory Medicine, 2007
- Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax, 2005
- COPD exacerbations: the importance of a standard definitionRespiratory Medicine, 2004
- Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.European Respiratory Journal, 2003
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002
- Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000
- Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)American Journal of Respiratory and Critical Care Medicine, 1996